StockData
Hemab Therapeutics Holdings, Inc. logo

Hemab Therapeutics Holdings, Inc. (COAG) stock

COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$39.15+0.09 (+0.23%)

Close on Nov 18, 2026Market cap $1.83BP/E –Yield –

Earnings

Hemab Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.58
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Hemab Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open––-$0.58Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026before the open––-$0.80Release
Q1 FY2026ended Mar 31, 2026May 21, 2026before the open––-$23.98Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Hemab Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Hemab Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Hemab Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?